Year: 2025
Type: article
Abstract: This paper reviews asthma treatment advancements, particularly short-acting β2 agonists (SABAs) and innovative therapies. While SABAs have been essential since the 1950s, low patient adherence often leads to overuse and poor outcomes. This review examines the pharmacology of inhaled SABAs and presents as-needed inhaled corticosteroids (ICS) with formoterol as a promising alternative for swift relief. With asthma remaining a critical global health issue, recent progress in pharmacotherapy—such as digital therapies, precision medicine, and new drug classes—offers new hope for better management. The analysis highlights the urgent need to tackle unmet requirements in cost, accessibility, and adherence, especially in resource-limited settings, to ensure optimal care for all patients.
Authors: Shaik Parveen, M. Rishitha, Ch. Niharika, G. Rajini
Language: English
Subfield: Physiology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4412962913